The reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
507.52MCHF
633.66M · vs all stocks (USD)
Updated Aug 21, 2026
Revenue (TTM)
1.12BCHF
1.40B · vs all stocks (USD)
Updated Aug 21, 2026
Profit Margin
-11.95%
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Beta
1.86x
vs all stocks
Updated Aug 21, 2026
52-Week Change
42.83%
vs all stocks
Updated Aug 21, 2026
Market Capitalization
507.52MCHF
633.66M · vs all stocks (USD)
Updated Aug 21, 2026
Enterprise Value
592.43MCHF
739.67M · vs all stocks (USD)
Updated Aug 21, 2026
Forward P/E
-9.90x
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Price to Sales (TTM)
0.4534x
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Price to Book (MRQ)
1.18x
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Enterprise to Revenue
0.5270x
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Enterprise to EBITDA
-6.87x
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Profit Margin
-11.95%
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Operating Margin
-7.69%
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Return on Assets (TTM)
-7.67%
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Return on Equity (TTM)
-35.88%
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Revenue (TTM)
1.12BCHF
1.40B · vs all stocks (USD)
Updated Aug 21, 2026
Revenue per Share (TTM)
29.04CHFUpdated Aug 21, 2026
Quarterly Revenue Growth
11.90%
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Gross Profit (TTM)
249.95MCHF
312.08M · vs all stocks (USD)
Updated Aug 21, 2026
EBITDA (TTM)
-86.27MCHF
-107.71M · vs all stocks (USD)
Updated Aug 21, 2026
Net Income (TTM)
-134.40MCHF
-167.80M · vs all stocks (USD)
Updated Aug 21, 2026
Operating Cash Flow (TTM)
-88.61MCHF
-110.64M · vs all stocks (USD)
Updated Aug 21, 2026
Levered Free Cash Flow (TTM)
-73.36MCHF
-91.60M · vs all stocks (USD)
Updated Aug 21, 2026
Trailing Annual Dividend Rate
0.00CHFUpdated Aug 21, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Aug 21, 2026
Payout Ratio
0.00%
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Revenue
1.02BCHFFY2024 · Dec 31, 2024
Cost of Goods Sold
800.50MCHFFY2024 · Dec 31, 2024
Gross Profit
216.54MCHFFY2024 · Dec 31, 2024
Operating Income
-104.22MCHF
-130.13M · vs all stocks (USD)
FY2024 · Dec 31, 2024
Pre-tax Income
-102.76MCHFFY2024 · Dec 31, 2024
Income Tax Expense
-5.50MCHFFY2024 · Dec 31, 2024
Net Income
-97.25MCHFFY2024 · Dec 31, 2024
EBIT
-83.22MCHFFY2024 · Dec 31, 2024
EBITDA (Income Statement)
-51.41MCHFFY2024 · Dec 31, 2024
Selling, General & Administrative
158.47MCHFFY2024 · Dec 31, 2024
Other Operating Expenses
17.89MCHFFY2024 · Dec 31, 2024
Non-operating Interest Income
2.38MCHFFY2024 · Dec 31, 2024
Non-operating Interest Expense
19.54MCHFFY2024 · Dec 31, 2024
EPS (Basic)
-4.06CHFFY2024 · Dec 31, 2024
EPS (Diluted)
-4.06CHFFY2024 · Dec 31, 2024
Basic Shares Outstanding
23.95MSharesFY2024 · Dec 31, 2024
Diluted Shares Outstanding
23.95MSharesFY2024 · Dec 31, 2024
Net Income from Continuing Operations
-97.25MCHFFY2024 · Dec 31, 2024
Preferred Stock Dividends
0.00CHFFY2024 · Dec 31, 2024
Operating Cash Flow
-78.64MCHFFY2024 · Dec 31, 2024
Free Cash Flow
-103.03MCHFFY2024 · Dec 31, 2024
Cash & Cash Equivalents (End of Period)
95.37MCHFFY2024 · Dec 31, 2024
Starting Profit (CF Statement)
-97.25MCHFFY2024 · Dec 31, 2024
Other Non-cash Items
2.03MCHFFY2024 · Dec 31, 2024
Change in Accounts Receivable (CF)
1.07MCHFFY2024 · Dec 31, 2024
Change in Other Assets/Liabilities
15.52MCHFFY2024 · Dec 31, 2024
Capital Expenditures
24.40MCHFFY2024 · Dec 31, 2024
Net Intangibles (CF)
-27.25MCHFFY2024 · Dec 31, 2024
Net Acquisitions
47.00MCHFFY2024 · Dec 31, 2024
Purchase of Investments
-90.40MCHFFY2024 · Dec 31, 2024
Sale of Investments
140.01MCHFFY2024 · Dec 31, 2024
Net Investing Cash Flow
121.01MCHFFY2024 · Dec 31, 2024
Long-term Debt Issuance
195.23MCHFFY2024 · Dec 31, 2024
Other Financing Charges
-220.88MCHFFY2024 · Dec 31, 2024
Net Financing Cash Flow
-25.65MCHFFY2024 · Dec 31, 2024
Shares Outstanding
50.98MSharesUpdated Aug 21, 2026
Float Shares
37.00MSharesUpdated Aug 21, 2026
% Held by Insiders
28.34%
vs all stocks
Updated Aug 21, 2026
% Held by Institutions
21.47%
vs all stocks
Updated Aug 21, 2026
Total Cash (MRQ)
159.48MCHF
199.11M · vs all stocks (USD)
Updated Aug 21, 2026
Total Cash per Share (MRQ)
3.31CHFUpdated Aug 21, 2026
Total Debt (MRQ)
288.64MCHF
360.38M · vs all stocks (USD)
Updated Aug 21, 2026
Total Debt to Equity (MRQ)
0.7056x
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Current Ratio (MRQ)
2.19x
vs Pharmaceutical Retailers peers
Updated Aug 21, 2026
Book Value per Share (MRQ)
8.50CHFUpdated Aug 21, 2026
Total Assets
778.13MCHF
971.54M · vs all stocks (USD)
FY2024 · Dec 31, 2024
Total Current Assets
213.57MCHFFY2024 · Dec 31, 2024
Total Liabilities
438.02MCHFFY2024 · Dec 31, 2024
Total Non-current Assets
564.57MCHFFY2024 · Dec 31, 2024
Total Non-current Liabilities
321.54MCHFFY2024 · Dec 31, 2024
Total Current Liabilities
116.48MCHFFY2024 · Dec 31, 2024
Cash & Cash Equivalents
95.37MCHFFY2024 · Dec 31, 2024
Accounts Receivable
54.01MCHFFY2024 · Dec 31, 2024
Inventory
37.08MCHFFY2024 · Dec 31, 2024
Accounts Payable
59.41MCHFFY2024 · Dec 31, 2024
Short-term Debt
4.26MCHFFY2024 · Dec 31, 2024
Long-term Debt
307.95MCHFFY2024 · Dec 31, 2024
Common Stock (Book)
445.05MCHFFY2024 · Dec 31, 2024
Retained Earnings
-596.93MCHFFY2024 · Dec 31, 2024
Total Shareholders' Equity
340.11MCHF
424.65M · vs all stocks (USD)
FY2024 · Dec 31, 2024
Treasury Stock
90.56MCHFFY2024 · Dec 31, 2024
52-Week Low
3.92CHFUpdated Aug 21, 2026
52-Week High
11.25CHFUpdated Aug 21, 2026
52-Week Change
42.83%
vs all stocks
Updated Aug 21, 2026
Beta
1.86x
vs all stocks
Updated Aug 21, 2026
50-Day MA
9.33CHFUpdated Aug 21, 2026
200-Day MA
6.67CHFUpdated Aug 21, 2026
Avg 10-Day Volume
304.98KSharesUpdated Aug 21, 2026
Avg 30-Day Volume
364.50KSharesUpdated Aug 21, 2026
Diluted EPS (TTM)
-4.58CHFUpdated Aug 21, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
It can cover near-term bills from cash alone, not just from inventory.
Reads
How does this company use capital?
Three Turnover Ratios Elevated
Collects fast, clears inventory fast, and pays suppliers fast too.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.